

University of Kentucky Hospital Chandler
Medical Center Lexington, Kentucky 40536

Cytogenetics Laboratory
Department of Pathology
Phone: (859) 257-3736
FAX: (859) 257-6838

PATIENT NAME:

MEDICAL RECORD # :

DATE OF BIRTH:

CYTOGENETICS REQUISITION - ONCOLOGY

Attending Physician		Pager #	Date/Time Specimen Collected:
Requesting Physician	Signature	Date/Time	

SPECIMEN (check one):

Deliver to HL423 University of Kentucky Hospital

Bone marrow aspirate in sodium heparin: Adults: 2-3 mL (4-5 mL if Multiple Myeloma FISH Panel** is ordered) Children: 1-3 mL	Lymph node:	Minimum: 5 mm x 5 mm x 5 mm
		Preferred: 10 mm x 10 mm x 10 mm
Peripheral blood for evaluation of leukemia/lymphoma: (may be substituted for bone marrow if peripheral WBC \geq 15,000 and blasts $>10\%$): All ages: 7-10 mL in sodium heparin	Tumor:	Minimum: 10 mm x 10 mm x 10 mm
	For the above specimens: Sterile Transport Media (RPMI) may be obtained from the Cytogenetics Lab during work hours, call 859-257-3736 and after hours from Lab Central Receiving, call 859-323-5431	
Formalin-fixed paraffin-embedded tissue (for FISH analysis only) Specimen fixation requirements: 10% Neutral Buffered Formalin 6-72 hours (6-48 hours preferred). No decalcification.	Other (specify):	

CLINICAL DIAGNOSIS (REQUIRED) :

TESTING REQUESTED (check all that apply):

<input type="checkbox"/>	Chromosome analysis only
<input type="checkbox"/>	Chromosome analysis and FISH – FISH TEST(S) MUST BE SELECTED ON THE REVERSE SIDE. FOR PANELS ALSO SELECT Complete OR Follow up*
<input type="checkbox"/>	FISH only – FISH TEST(S) MUST BE SELECTED ON THE REVERSE SIDE. FOR PANELS ALSO SELECT Complete OR Follow up*

*Follow up: Only previously abnormal probes from the specific panel will be performed.

** For ANY Multiple Myeloma FISH orders additional specimen is needed, at least 2 mL's of unclotted bone marrow is required to perform the CD138 Cell Sort which isolates plasma cells from the bone marrow and provides an enriched population for FISH testing. For inadequate MM specimens FISH probes will be prioritized over conventional chromosome analysis and probes will be performed in order of risk stratification according to the most recent guideline as per lab policy.

LAB USE ONLY

Lab # _____

Date/Time received _____

CDM's _____

FISH PANEL(S) REQUESTED: Please select from list below and choose Complete OR Follow up*

*Follow up: Only previously abnormal probes from the specific panel will be performed.

Adult AML Panel		Complete	Follow up	Lymphoma Panel, Follicular Center Cell		Complete	Follow up
Adult B-cell ALL Panel		Complete	Follow up	Lymphoma Panel-Aggressive B-cell		Complete	Follow up
Adult T-cell ALL Panel		Complete	Follow up	Lymphoma Panel, Marginal Zone		Complete	Follow up
Burkitt's leukemia/lymphoma Panel		Complete	Follow up	MDS Panel		Complete	Follow up
CLL Panel		Complete	Follow up	MPD/MPN/MPS Panel		Complete	Follow up
Pediatric B-cell ALL Panel		Complete	Follow up	MPD/MPN/MPS with eosinophilia Panel		Complete	Follow up
Pediatric B-cell ALL (HR-high risk) Panel		Complete	Follow up	**For inadequate MM specimens probes will be performed in order of risk stratification according to the most recent guideline as per lab policy.			
Pediatric T-cell ALL Panel		Complete	Follow up				
Pediatric AML Panel		Complete	Follow up	**Multiple Myeloma Initial Prognosis Panel (Tier 1 with reflex to Tier 2)			
Ph-like ALL Panel		Complete	Follow up	**Multiple Myeloma Follow up Panel (Only previously abnormal probes)			

INDIVIDUAL FISH TEST(S) REQUESTED: Please select from list below

ABL1 (ALL) t(9)(q34.12-q34.13)	IGH (B-ALL, MM, Lymphoma Marginal Zone) (14q32.3 rearrangements)
ABL2 (ALL) t(1)(q25.2)	IGH/BCL2 (Follicular Lymphoma) t(14;18)
ABL1/ASS1/BCR (CML,ALL,AML) t(9;22)	IGH/MAF (Multiple Myeloma) t(14;16)
ATM/TP53 (CLL) (del 11q/del 17p)	IGH/MAFB (Multiple Myeloma) t(14;20)
BCL6 (NHL) t(3q27)	JAK2 (ALL) (9p24 rearrangements)
BIRC3/MALT1 (Lymphoma) t(11;18)	KMT2A (ALL, AML) t(11)(q23)
CBFB (AML) (inv 16), t(16;16)	MECOM (MDS, AML) inv(3), t(3;3) & variants
CCND1/IGH (Mantle Cell Lymphoma, Multiple Myeloma) t(11;14)	MYB (ALL,CLL/SLL,NHL) del 6q
CCND3/IGH (Multiple Myeloma) t(6;14)	MYC (Burkitt, L3 ALL) t(8;14) & variant
CDKN2A/D9Z1 (ALL) (del 9p)	MYC/IGH (Burkitt lymphoma, L3 ALL) t(8;14)
CRLF2 (Xp22.3 or Yp11.2 rearrangement)	MYH11/CBFB (AML) (inv 16), t(16;16)
D4Z1, D10Z1, D17Z1 Hyperdiploidy analysis (B-cell ALL)	NUP98 (AML) (11p15.4 rearrangement)
D5S23,D5S721/EGR1 (MDS,MPD, AML) Monosomy 5/del 5q	PDGFRA/FIP1L1 (CEL,HES) del 4q12, t(4q12)
D7Z1/D7S486 (MDS,MPD, AML) Monosomy 7/del 7q	PDGFRB (CMML, aCML,CEL,MPD) t(5;12) & variants
D8Z2/D20S108 (MDS,MPD, AML) (trisomy 8/del 20q)	PML/RARA (APL) t(15;17)
D12Z3/D13S319/LAMP1 (CLL) (+12/del 13q/monosomy13)	P2RY8 (Xp22.3 or Yp11.2 rearrangement)
DEK/NUP214 (AML,MDS) t(6;9)	RB1/LAMP1 (Retinoblastoma) del 13q/monosomy 13
DXZ1/DYZ3 (sex mismatch BMT engraftment monitoring)	TCF3(E2A) (ALL) t(1;19) & variants
ETV6/RUNX1 (B-cell ALL) t(12;21)	TCL1 (T-cell ALL) t(14)(q32)
EWSR1 (Ewing's sarcoma, PNET) t(11;22) & variants	TP53 (del 17p)
FGFR1 (Myeloproliferative syndrome) (del 8p11)	TRA/D (T-cell ALL) t(14)(q11)
FGFR3/IGH (Multiple Myeloma) t(4;14)	TRB (T-cell ALL) t(7)(q34)
FLT3 (ALL, MLNE) del(13q12.2)	RUNX1T1/RUNX1 (AML) t(8;21)

FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE FISH TEST(S) REQUESTED: Please select from list below

1p/19q codeletion (brain/glioma)	Lymphoma Panel (BCL6, MYC, BCL2)
EWSR1 rearrangement sarcoma	BCL2 rearrangement lymphoma
HER2 amplification breast and upper gastrointestinal	BCL6 rearrangement lymphoma
MDM2 amplification sarcoma	MYC rearrangement lymphoma
SS18 rearrangement sarcoma	

LAB USE ONLY

Lab # _____

Date/Time received _____

CDM's _____